InvestorsHub Logo
Followers 797
Posts 50895
Boards Moderated 1
Alias Born 12/12/2004

Re: None

Sunday, 08/21/2022 11:04:15 PM

Sunday, August 21, 2022 11:04:15 PM

Post# of 1456
Expected Upcoming Milestones

-- Zilovertamab, our ROR1 antibody program

-- Initiation of global registrational Phase 3 Study ZILO-301, in
September 2022

-- Interim clinical data update for patients with MCL and CLL treated
with zilovertamab plus ibrutinib in ongoing Phase 1/2 clinical
study CIRM-0001, in the fourth quarter of 2022

-- ONCT-808, lead candidate in our autologous ROR1-targeted CAR-T cell
therapy program

-- Investigational New Drug (IND) application submission in August
2022

-- ONCT-534, lead candidate in our DAARI program

-- FDA pre-IND interactions in the fourth quarter of 2022

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCT News